Jafar rezaie, PhD,

                                                                                        Assistant Professor

(Download CV below )


Contact information:

Tell  : +984433195073

Cell phone: +989148548503

Email:  J.rezaie88@gmail.com

. Address: Floor 3, Cellular and Molecular Medicine Institute., Shafa St., Ershad Blvd., Urmia, West Azarbaijan, Iran


         I am working in the field of Extracellular Vesicles (EVs) biology especially focused on exosome signaling pathway in cancer. EVs contribute to physiological and pathological processes in a specific manner. In the field of cancer biology, scientists have interested in studying of EVs biology  as well as in the application of EVs in diagnosis and treatment of cancers. My scientific interests have focused on the study of small vesicles called exosomes, secreted by angiogeneic and tumor cells, which play many roles in communications between tumors. Here, we are interested in lightening the key role of EVs in cancerous tissues In Vivo/In Vitro, and also following their bio-application. Therapeutic application of exosomes may comprise using them  as drug delivery system, biomarker tool, and exosomes-therapy for many diseases. 


Research Focus

 Tumor derived exosomes kinetic

  Biomarker in cancer diseases

 Cancer immunotherapy

 Exosome-based drug delivery

List of publications:  https://scholar.google.com/citations?user=t-D_hUEAAAAJ&hl=en


Research Team

Dr. Jabbari (Radiobiologist)

Dr. Soraya (pharmacologist)

Dr. Asghari (Oncologist)

Dr. Rahbarghazi (Pathologist)

Dr. Khaksar (Cardio-Phatologist)

Dr. Akbari (Neurobiologist)

Dr. Akbari (Nanomedicine, Nanoparticles)


Mr. Aftab

Mrs. Abaspour

Mrs. Etemadi

Mrs. Feghhi


Research Experience


Well-experienced in stem cell biology with focus on cell isolation, expansion and differentiation.

Experienced in the field of stem cells such as Mesenchymal, Endothelial, Myocytes, and CRI-D2 cells.

Experienced in Exosome signaling pathway and angiogenesis mechanism studies, method development, validation, and design of in vivo or in vitro models studies.

Well-experienced in proteomics methods and related softwares especially Western Blot analysis.

Well-experienced in genomics methods and related softwares especially real time PCR investigation.

Well-experienced in cell staining and tracking methods with focus on immunocytochemistry and immunofluorescence, flow cytometry and techniques.

Experienced in proposal writing and manuscript preparation.

 Familiar to a panel of softwares especially SPSS, GIMP, InkScape , Sketchup, Flow Jo,  Image  J, Oligo 7 , Perlprimer, Rotor Gene ,... 






What is exosomes? 


      Exosomes are a subtype of extracellular vesicles (EVs) that represent a new tool in cell to cell communication through shuttling bio-molecules between cells. Exosomes released from various stem cells and committed cell types in size of 30-120nm into extracellular matrix (ECM) following constitutive or induced state. According to studies, exosome can be found in bio-fluids such as plasma, breast milk, urine, semen, amniotic fluid, ascites fluid, cerebrospinal fluid, bile, saliva, bronchoalveolar lavage, and also urine. Interestingly, exosomes purification from various cells represent common endosomal pathway proteins for example tetraspanins (CD9, CD63, CD81), Alix, heat shock proteins (Hsc70 and Hsp90), and tumor susceptibility gene 101 (Tsg101). An intriguing aspect of exosomes, these EVs actively participate to transfer a lot of molecules the same as a pocket covering their lumen contents from several RNAases and proteases. Last proteomic and transcriptomic analyses have been employed to discover exosomes nucleic acid and protein cargoes as well as lipid contents. In addition, research into exosomes compositions reveal the presence of many lipid rafts, proteins, enzymes, and sugar chains on exosomes surrounding membrane that governing exosome function. In the past decade, scientific reports demonstrated the key role of these vesicles in normal physiological process and pathogenesis of tumor and non-tumor diseases. Intensive efforts are in processing to elucidate pivotal role of these EVs in pathogenesis of diseases, which could expectantly address dynamic of exosome signaling pathways and clinical application of them in diagnosis and therapeutic approaches. Exosomes from diverse cellular origins have been revealed to harbor common molecules present in the parent cell, and consequently could be used rather than stem cells to persuade effective therapy. Indeed, exosome-based therapy could probably improve several issues about the safety and practical limitations associated with the application of stem/progenitor cells, such as the risk of maldifferentiation. It seems that regardless of intensive research in this field, there are still a lot of unclear question about exosome signaling pathways and their clinical usage that need to be considered in the future investigations.


Future prospect:

Along with the important role of the EVs in diseases, preconditioning or engineering of EVs surface membrane or their cargoes may result in disease specificity and efficacy. It seems that EVs represents a remarkable alternative for regenerative medicine and may also for diagnosing  diseases as a novel biomarker. Further endeavors still need to understand how EVs affects target cells? And how to engineer EVs to improve their efficacy in regenerative medicine? Furthermore, EVs from which cells are an excellent applicable candidate for therapeutic approaches?   







Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications

In cancer therapy, early diagnosis and effective therapy hold great importance for increasing survival and quality of patients’ lifespan. Studies have recently revealed that almost every type of cells including tumor cells abundantly release small vesicles known as extracellular vesicles (EVs) into the extracellular milieu. EVs carry a repertoire of biological molecules including nucleic acids, proteins, lipids, and carbohydrates and transport their cargo between cells in the vicinity as well as distantly located cells and hence act as messengers of intercellular communication. A growing body of evidence indicates that nucleic acids such as microRNAs (miRNAs) transferring by EVs participate to create a conducive tumor environment. As EV-associated miRNAs are tissue-specific and present in most biological fluids, they hold great potential for clinical application in cancer early diagnosis, prognosis, and treatment response. Furthermore, exosomes can serve as drug delivery vehicles transferring miRNAs as well as therapeutic agents to target cells. These nano-vesicles exhibit ideal properties in comparison with the synthetic carriers that attracted scientist’s attention in the field of nanotechnology medicine. Scientists have employed different strategies to build exosomes-based drug delivery system. In general, two methods (direct engineering and indirect engineering) are being utilized for produce artificial exosomes. Para-clinical data have confirmed the beneficial effects of engineering exosomes. In spite of enthusiastic results obtained by engineered exosomes, however, there is an increasing concern over the use of optimal exosomal loading method and the safety of engineered exosomes in clinical trial is still unclear


DOI: 10.1186/s12964-019-0390-y



















   دانلود : CURRICULUM_VITAE.pdf           حجم فایل 368 KB